NASDAQ: RGNX · Life Sciences · 4 alerts · CIK 1590877
Share price
$7.32Close, Nov 16
Market cap
$484M
Shares outstanding
66.12MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Regenxbio Inc. filings on SEC EDGAR ↗
REGENXBIO Inc. reported total assets of $466.0 million as of September 30, 2026, with a significant increase in cash and cash equivalents to $95.8 million compared to $34.5 million at year-end 2025. The company is currently managing clinical holds on its RGX-121 and RGX-111 programs while continuing development partnerships with AbbVie and Nippon Shinyaku.
REGENXBIO reported Q3 2026 financial results, highlighting progress toward a BLA submission for its Duchenne muscular dystrophy gene therapy RGX-202 in Q1 2027. The company also expects topline pivotal data for its wet AMD candidate sura-vec in Q4 2026, with global regulatory submissions planned for 2027.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028. With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”
Curran Simpson, President and Chief Executive Officer of REGENXBIO